Dr Stephen Waters

Dr Stephen Waters has been appointed interim executive VP and chief scientific officer of DiaMedica Inc, Winnipeg, a developer of treatments for Type 2 diabetes. Walters replaces Dr Wayne Lautt, who discovered a key mechanism of insulin resistance that led to the founding of DiaMedica. A professor of pharmacology and therapeutics at the Univ of Manitoba, he is returning to basic research. Waters has held various senior positions with MGI Pharma and Ohmeda Pharmaceutical Products over a 24-year career. He holds an MSc in toxicology and PhD in pharmacology and toxicolo